Thyroid Disease 2007: The Pharmacist, Patient, and Physician Connection

Thyroid Disease 2007: The Pharmacist, Patient, and Physician Connection
Please read through the following information and click continue.

ACPE Universal Program Number: 207-000-07-138-H01-P
Release Date: October 16, 2007
Expiration Date: October 16, 2010

Statement of Need
The prevalence of thyroid dysfunction in the United States is higher than that of depression, diabetes, and HIV. While levothyroxine sodium has remained the therapeutic gold standard for decades, some studies show that up to 40% of patients on LT4 therapy are suboptimally managed. Thyroid Disease 2007: The Pharmacist, Patient, and Physician Connection will explore the ways in which collaboration can optimize patient care. Our distinguished faculty will use cases to examine the ways in which LT4 treatment can be improved and the clinical consequences of inadequate care at the pharmacy, the clinic and at home.

Learning Objectives
Upon successful completion of this activity, the pharmacist should be better able to:

Name 3 clinical consequences of thyroid dysfunction.
Outline strategies to avoid fluctuating thyroid hormone levels.
Describe the impact of combining T3 with LT4 therapy.

Target Audience
The target audience for this program is pharmacists.

Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:

Review the content of the activity.

Successfully complete the post-test (12 out of 16 correct answers or higher).

You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.

Fee
There is no fee for this activity.

Commercial Support
Commercial Support Provided by Abbott.

Accreditation

Pharmacists
ACPE logo NCPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program will provide 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit under the number 207-000-07-138-H01-P.

Faculty
E. Chester Ridgeway, MD (click on faculty name to view biography)
Professor of Medicine
University of Colorado Health Sciences Center
Head Division, Endocrinology, Metabolism & Diabetes
Aurora, Colorado

Anthony J. Busti, Pharm.D., BCPS (click on faculty name to view biography)
Associate Professor
Texas Tech University Health Sciences Center
Dallas, Texas

Disclosure Declaration
It is the policy of the National Community Pharmacists Association (NCPA) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.

Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Software Requirements

PC Windows 2000 Internet Explorer 5.5 or Firefox *Adobe Acrobat Reader	MAC Mac OS 10.2.8 Safari *Adobe Acrobat Reader
*REQUIRED TO VIEW PRINTABLE VERSION OF CE LESSON

Continue